Iambic Therapeutics (NASDAQ:IAM – Get Free Report) released its quarterly earnings results on Monday. The company reported ($6.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($5.90), Zacks reports. The company had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $42.50 million.
Iambic Therapeutics Stock Up 3.9%
Shares of NASDAQ IAM traded up $0.55 during midday trading on Wednesday, hitting $14.77. The company’s stock had a trading volume of 149,423 shares, compared to its average volume of 686,630. Iambic Therapeutics has a 1-year low of $9.60 and a 1-year high of $25.00.
Wall Street Analyst Weigh In
IAM has been the topic of a number of recent analyst reports. Wall Street Zen upgraded shares of Iambic Therapeutics to a “hold” rating in a report on Saturday, November 7th. Citigroup started coverage on Iambic Therapeutics in a research note on Monday, November 9th. They set a “buy” rating and a $22.00 target price for the company. Zacks Research initiated coverage on Iambic Therapeutics in a research report on Tuesday, November 10th. They set a “hold” rating on the stock. JPMorgan Chase & Co. started coverage on Iambic Therapeutics in a research note on Monday, November 9th. They issued an “overweight” rating and a $22.00 price target on the stock. Finally, Jefferies Financial Group began coverage on Iambic Therapeutics in a research note on Tuesday, November 10th. They issued a “buy” rating and a $35.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $27.25.
Insider Transactions at Iambic Therapeutics
In related news, Director Evan Lockwood Rachlin bought 718,750 shares of the firm’s stock in a transaction on Friday, October 16th. The stock was bought at an average cost of $16.00 per share, for a total transaction of $11,500,000.00. Following the completion of the purchase, the director directly owned 2,588,248 shares in the company, valued at approximately $41,411,968. The trade was a 38.45% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Iambic Therapeutics Company Profile
Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.
Read More
- Five stocks we like better than Iambic Therapeutics
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
- AMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
